VERAXA Biotech and Ardigen Partner to Boost BiTAC Pipeline with AI

VERAXA Biotech (NASDAQ: VRXA), a clinical-stage biotechnology company, has announced a strategic collaboration with Ardigen S.A., an AI-driven bioinformatics company, to accelerate the development of its BiTAC® pipeline of T-cell engagers and future antibody-drug conjugates (ADCs). The partnership will focus on creating AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which aims to improve tumor targeting while reducing off-target toxicity. By integrating artificial intelligence into its R&D strategy, VERAXA hopes to enhance target selection by analyzing large preclinical and clinical datasets, including programs that showed efficacy but failed due to toxicity. This collaboration is expected to strengthen the development of precision oncology therapies and improve long-term drug development success rates.

VERAXA Biotech AG, headquartered in Switzerland, is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). Its proprietary BiTAC platform is designed to engage T cells to attack tumors more precisely. The collaboration with Ardigen will leverage advanced AI algorithms to sift through vast amounts of data, potentially unlocking novel target combinations that could lead to safer and more effective cancer treatments. This move aligns with the broader industry trend of using AI to streamline drug discovery and development.

For more details, the full press release is available at https://ibn.fm/GLFg2. Investors can stay updated on VRXA news at the company's newsroom http://ibn.fm/VRXA. The announcement was distributed by InvestorWire, a part of IBN's Dynamic Brand Portfolio, which provides wire-grade press release syndication and enhanced corporate communications solutions.